Krystal Biotech, Inc. Common Stock KRYS
i
Market dataready · fetched 2026-11-04T03:52:53.833Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:33:54.457754326Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-04T03:52:53.391400+00:00
Krystal Biotech, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 332.63 | 39.5% | 9.0% | 283.41 | 48.7% | 9.1% |
| 25Δ | 326.95 | 37.6% | 7.4% | 288.62 | 48.7% | 7.9% |
| 30Δ | 322.91 | 37.5% | 6.4% | 293.19 | 48.7% | 6.9% |
| 35Δ | 319.06 | 37.1% | 5.5% | 297.53 | 48.7% | 5.9% |
| 40Δ | 315.67 | 36.0% | 4.7% | 301.78 | 49.0% | 5.2% |
| 45Δ | 312.28 | 34.9% | 3.9% | 305.91 | 49.5% | 4.5% |
| 50Δ | 309.08 | 34.0% | 3.3% | 310.03 | 50.1% | 3.9% |
| 55Δ | 306.27 | 33.6% | 2.8% | 314.34 | 50.0% | 3.3% |
| 60Δ | 303.47 | 33.3% | 2.4% | 318.66 | 49.9% | 2.7% |
| 65Δ | 300.66 | 32.9% | 1.9% | 324.00 | 51.5% | 2.3% |
| 70Δ | 297.79 | 32.2% | 1.6% | 329.81 | 53.8% | 1.9% |
| 75Δ | 294.90 | 31.4% | 1.3% | 338.52 | 58.6% | 1.6% |
| 80Δ | 292.00 | 30.6% | 1.0% | 351.93 | 67.0% | 1.3% |
20Δ
- Pseudo strike
- 332.63
- IV
- 39.5%
- B/E move
- 9.0%
- Pseudo strike
- 283.41
- IV
- 48.7%
- B/E move
- 9.1%
25Δ
- Pseudo strike
- 326.95
- IV
- 37.6%
- B/E move
- 7.4%
- Pseudo strike
- 288.62
- IV
- 48.7%
- B/E move
- 7.9%
30Δ
- Pseudo strike
- 322.91
- IV
- 37.5%
- B/E move
- 6.4%
- Pseudo strike
- 293.19
- IV
- 48.7%
- B/E move
- 6.9%
35Δ
- Pseudo strike
- 319.06
- IV
- 37.1%
- B/E move
- 5.5%
- Pseudo strike
- 297.53
- IV
- 48.7%
- B/E move
- 5.9%
40Δ
- Pseudo strike
- 315.67
- IV
- 36.0%
- B/E move
- 4.7%
- Pseudo strike
- 301.78
- IV
- 49.0%
- B/E move
- 5.2%
45Δ
- Pseudo strike
- 312.28
- IV
- 34.9%
- B/E move
- 3.9%
- Pseudo strike
- 305.91
- IV
- 49.5%
- B/E move
- 4.5%
50Δ
- Pseudo strike
- 309.08
- IV
- 34.0%
- B/E move
- 3.3%
- Pseudo strike
- 310.03
- IV
- 50.1%
- B/E move
- 3.9%
55Δ
- Pseudo strike
- 306.27
- IV
- 33.6%
- B/E move
- 2.8%
- Pseudo strike
- 314.34
- IV
- 50.0%
- B/E move
- 3.3%
60Δ
- Pseudo strike
- 303.47
- IV
- 33.3%
- B/E move
- 2.4%
- Pseudo strike
- 318.66
- IV
- 49.9%
- B/E move
- 2.7%
65Δ
- Pseudo strike
- 300.66
- IV
- 32.9%
- B/E move
- 1.9%
- Pseudo strike
- 324.00
- IV
- 51.5%
- B/E move
- 2.3%
70Δ
- Pseudo strike
- 297.79
- IV
- 32.2%
- B/E move
- 1.6%
- Pseudo strike
- 329.81
- IV
- 53.8%
- B/E move
- 1.9%
75Δ
- Pseudo strike
- 294.90
- IV
- 31.4%
- B/E move
- 1.3%
- Pseudo strike
- 338.52
- IV
- 58.6%
- B/E move
- 1.6%
80Δ
- Pseudo strike
- 292.00
- IV
- 30.6%
- B/E move
- 1.0%
- Pseudo strike
- 351.93
- IV
- 67.0%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 47.14% | |
| 47.19% | |
| 47.47% | |
| 48.25% | |
| 48.33% | |
| 49.03% | |
| 48.83% | |
| 49.17% | |
| 49.15% | |
| 50.09% |
Biotechnology
KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego,…
More →KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins…
More →KYTX
Description unavailable
More →KZIA
Kazia Therapeutics Limited, a biotechnology company focused on oncology, develops anticancer drugs. The company is headquartered in Sydney, Australia.
More →LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.…
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →